Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ: 007370)

Jin Yang Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	111,149	94,111	76,264	62,839	49,525	47,351
Other Revenue	-	-	-0	-	-	-
Revenue	111,149	94,111	76,264	62,839	49,525	47,351
Revenue Growth (YoY)	26.58%	23.40%	21.36%	26.88%	4.59%	1.04%
Cost of Revenue	42,919	36,652	30,613	28,856	23,242	23,289
Gross Profit	68,231	57,459	45,651	33,984	26,282	24,063
Selling, General & Admin	57,419	46,381	33,981	27,965	24,282	23,932
Other Operating Expenses	193.03	170.02	139.73	146.93	108.97	111.7
Operating Expenses	60,622	48,374	34,513	27,020	22,022	24,279
Operating Income	7,609	9,085	11,138	6,964	4,261	-216.33
Interest Expense	-1,661	-1,374	-1,285	-208.28	-162.88	-302.04
Interest & Investment Income	318.01	1,472	356.59	16.99	68.29	174.86
Currency Exchange Gain (Loss)	-7.82	-1.69	3.53	-0.2	-0.03	1.84
Other Non Operating Income (Expenses)	2,815	937.36	839.11	3,913	387.95	1,576
EBT Excluding Unusual Items	9,073	10,119	11,053	10,685	4,554	1,234
Gain (Loss) on Sale of Investments	26,242	2,253	3,132	1,438	1,979	828.12
Gain (Loss) on Sale of Assets	0.82	0.86	24.9	9.53	0.6	7.67
Asset Writedown	-	-	325.53	-	-	-
Other Unusual Items	-91.59	210.2	-	-	-	-
Pretax Income	35,224	12,583	14,535	12,132	6,533	2,070
Income Tax Expense	7,092	-75.78	2,227	2,594	1,305	422.84
Net Income	28,132	12,659	12,308	9,538	5,229	1,647
Net Income to Common	28,132	12,659	12,308	9,538	5,229	1,647
Net Income Growth	117.21%	2.85%	29.05%	82.41%	217.50%	76.48%
Shares Outstanding (Basic)	11	11	11	11	11	11
Shares Outstanding (Diluted)	13	12	12	11	11	11
Shares Change (YoY)	4.40%	-0.04%	10.33%	1.27%	-0.27%	-0.35%
EPS (Basic)	2590.97	1174.67	1115.00	853.00	468.00	147.00
EPS (Diluted)	2160.83	1112.00	986.00	843.00	468.00	147.00
EPS Growth	107.83%	12.78%	16.96%	80.13%	218.37%	77.11%
Free Cash Flow	-74,699	7,851	4,230	-545.86	4,881	6,472
Free Cash Flow Per Share	-5743.97	629.22	338.84	-48.25	436.92	577.73
Gross Margin	61.39%	61.05%	59.86%	54.08%	53.07%	50.82%
Operating Margin	6.85%	9.65%	14.61%	11.08%	8.60%	-0.46%
Profit Margin	25.31%	13.45%	16.14%	15.18%	10.56%	3.48%
Free Cash Flow Margin	-67.21%	8.34%	5.55%	-0.87%	9.86%	13.67%
EBITDA	10,179	11,740	13,429	9,117	6,308	1,898
EBITDA Margin	9.16%	12.47%	17.61%	14.51%	12.74%	4.01%
D&A For EBITDA	2,570	2,655	2,291	2,154	2,048	2,115
EBIT	7,609	9,085	11,138	6,964	4,261	-216.33
EBIT Margin	6.85%	9.65%	14.61%	11.08%	8.60%	-0.46%
Effective Tax Rate	20.13%	-	15.32%	21.38%	19.97%	20.43%
Advertising Expenses	-	3,869	2,541	2,125	2,351	2,157

Source: S&P Capital IQ. Standard template. Financial Sources.